Thyrotropin-secreting pituitary adenomas (TSH-omas) present with signs and symptoms of hyperthyroidism and they are characterized by elevated serum levels of free thyroid hormones with measurable TSH levels. TSH-omas are very infrequent, accounting for less than 1% of all pituitary adenomas, thus representing a very rare cause of hyperthyroidism. For this reason, data collected on these rare disorders are relatively few, but some new researches shed new light on the etiopathogenesis, the diagnosis and the treatment of such a remarkable disease. Since the same biochemical picture is present in the syndromes of thyroid hormone resistance (RTH), in particular in the form of pituitary RTH, failure in distinguishing these clinical entities may lead to improper patient management. Conversely, early diagnosis and correct treatment of TSH-omas may prevent the occurrence of neurological and endocrinological complications, thus leading to a better rate of cure. In the present short review article, the most relevant recent advances in the pathophysiology of TSH-omas are described.

A 2019 update on TSH-secreting pituitary adenomas / P. Beck-Peccoz, C. Giavoli, A. Lania. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 42:12(2019 Dec), pp. 1401-1406. [10.1007/s40618-019-01066-x]

A 2019 update on TSH-secreting pituitary adenomas

P. Beck-Peccoz
Primo
;
C. Giavoli
Secondo
;
2019

Abstract

Thyrotropin-secreting pituitary adenomas (TSH-omas) present with signs and symptoms of hyperthyroidism and they are characterized by elevated serum levels of free thyroid hormones with measurable TSH levels. TSH-omas are very infrequent, accounting for less than 1% of all pituitary adenomas, thus representing a very rare cause of hyperthyroidism. For this reason, data collected on these rare disorders are relatively few, but some new researches shed new light on the etiopathogenesis, the diagnosis and the treatment of such a remarkable disease. Since the same biochemical picture is present in the syndromes of thyroid hormone resistance (RTH), in particular in the form of pituitary RTH, failure in distinguishing these clinical entities may lead to improper patient management. Conversely, early diagnosis and correct treatment of TSH-omas may prevent the occurrence of neurological and endocrinological complications, thus leading to a better rate of cure. In the present short review article, the most relevant recent advances in the pathophysiology of TSH-omas are described.
Central hyperthyroidism; Free T3; Free T4; Resistance to thyroid hormones; Somatostatin analogs; Thyrotropin; Thyrotropin-secreting pituitary adenoma; Transsphenoidal surgery; TSH-oma
Settore MED/13 - Endocrinologia
dic-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
s40618-019-01066-x.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 445.4 kB
Formato Adobe PDF
445.4 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/707454
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 46
social impact